13461-16-0

Basic information

• Product Name: NNDIMETHYLETHYLENETHIOUREA
• Synonyms: NNDIMETHYLETHYLENETHIOUREA;1,3-dimethyl-2-imidazolidinethion;1,3-dimethyl-2-Imidazolidinethione;2-Imidazolidinethione,1,3-dimethyl-;1,3-Dimethylimidazolidine-2-thione
• CAS NO: 13461-16-0
• Molecular Formula: C₅H₁₀N₂S
• Molecular Weight: 130.21
• Mol File: 13461-16-0.mol
• Article Data: 19

Chemical Properties

• Melting Point: 110-112 °C(Solv: water (7732-18-5))
• Boiling Point: 282.6 °C at 760 mmHg
• Flash Point: 124.7 °C
• Appearance: /
• Density: 1.17 g/cm³
• Vapor Pressure: 0.00333mmHg at 25°C
• Refractive Index: 1.6
• PKA: 1.50±0.20(Predicted)
• CAS DataBase Reference: NNDIMETHYLETHYLENETHIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: NNDIMETHYLETHYLENETHIOUREA(13461-16-0)
• EPA Substance Registry System: NNDIMETHYLETHYLENETHIOUREA(13461-16-0)

Safety Data

• Hazardous Substances Data: 13461-16-0(Hazardous Substances Data)

Usage

Description

N,N-dimethylethylenethiourea (DMTU) is a chemical compound that serves as a rubber vulcanization accelerator and antioxidant in the rubber industry, enhancing the durability and heat resistance of rubber materials. It also exhibits applications in the production of agrochemicals and metalworking fluids, and due to its strong inhibitory effect on nitric oxide synthase, it holds potential as a therapeutic agent for treating nitric oxide-related conditions.

Uses

Used in Rubber Industry:
NNDIMETHYLETHYLENETHIOUREA is used as a rubber vulcanization accelerator and antioxidant for improving the durability and heat resistance of natural and synthetic rubbers.
Used in Agrochemical Production:
NNDIMETHYLETHYLENETHIOUREA is used as an ingredient in the production of herbicides, fungicides, and pesticides, contributing to the effectiveness of these products in controlling plant diseases and pests.
Used in Metalworking Fluids:
NNDIMETHYLETHYLENETHIOUREA is used in the formulation of metalworking fluids to enhance their performance and protect metal surfaces during manufacturing processes.
Used in Pharmaceutical Applications:
NNDIMETHYLETHYLENETHIOUREA is used as a potential therapeutic agent for treating conditions related to nitric oxide imbalance, such as cardiovascular and neurological diseases, due to its strong inhibitory effect on nitric oxide synthase.
It is crucial to handle NNDIMETHYLETHYLENETHIOUREA with care due to its toxic and hazardous nature, ensuring safety in its applications across various industries.

InChI:InChI=1/C5H10N2S/c1-6-3-4-7(2)5(6)8/h3-4H2,1-2H3

Upstream product

• 96-45-7 N,N'-ethylenethiourea 
• 74-88-4 methyl iodide 
• 80-73-9 1,3-dimethyl-2-imidazolidinone 
• 58708-58-0 disodium N,N'-dimethylethylenebisdithiocarbamate 
• 6160-65-2 1,1'-Thiocarbonyldiimidazole 
• 110-70-3 N,N`-dimethylethylenediamine 
• 67-68-5 dimethyl sulfoxide 
• 14103-77-6 1,3-dimethylimidazolidine 
• 23309-78-6 N-(2-hydroxyethyl)-N,N'-dimethylthiourea 
• 917-54-4 methyllithium 
• 1911-01-9 1,1',3,3'-tetramethyl-2,2'-biimidazolidinylidene 
• 75-15-0 carbon disulfide 
• 61191-41-1 methyl iodide salt of N,N'-dimethylimidazolidine-2-thione 
• 58708-60-4 N,N'-Dimethyl-2-aminoethan-dithiocarbaminsaeure 

Downstream Products

• 80-73-9 1,3-dimethyl-2-imidazolidinone 
• 286-28-2 cyclohexene sulfide 
• 33877-15-5 (R)-(+)-styrene sulfide 
• 1911-01-9 1,1',3,3'-tetramethyl-2,2'-biimidazolidinylidene 
• 78872-76-1 phenylmethane dithiol 
• 131538-00-6 4-mercaptomethyl-1,8-dimercapto-3,6-dithiaoctane 
• 100-53-8 phenylmethanethiol 

Relevant articles and documents

Metal-Free C?H Borylation of N-Heteroarenes by Boron Trifluoride

Organoboron compounds are essential reagents in modern C?C coupling reactions. Their synthesis via catalytic C?H borylation by main group elements is emerging as a powerful tool alternative to transition metal based catalysis. Herein, a straightforward metal-free synthesis of aryldifluoroboranes from BF3 and heteroarenes is reported. The reaction is assisted by sterically hindered amines and catalytic amounts of thioureas. According to computational studies the reaction proceeds via frustrated Lewis pair (FLP) mechanism. The obtained aryldifluoroboranes are further stabilized against destructive protodeborylation by converting them to the corresponding air stable tetramethylammonium organotrifluoroborates.

Precursor reaction kinetics control compositional grading and size of CdSe1-: XSx nanocrystal heterostructures

We report a method to control the composition and microstructure of CdSe1-xSx nanocrystals by the simultaneous injection of sulfide and selenide precursors into a solution of cadmium oleate and oleic acid at 240 °C. Pairs of substituted thio- and selenoureas were selected from a library of compounds with conversion reaction reactivity exponents (kE) spanning 1.3 × 10-5 s-1 to 2.0 × 10-1 s-1. Depending on the relative reactivity (kSe/kS), core/shell and alloyed architectures were obtained. Growth of a thick outer CdS shell using a syringe pump method provides gram quantities of brightly photoluminescent quantum dots (PLQY = 67 to 90%) in a single reaction vessel. Kinetics simulations predict that relative precursor reactivity ratios of less than 10 result in alloyed compositions, while larger reactivity differences lead to abrupt interfaces. CdSe1-xSx alloys (kSe/kS = 2.4) display two longitudinal optical phonon modes with composition dependent frequencies characteristic of the alloy microstructure. When one precursor is more reactive than the other, its conversion reactivity and mole fraction control the number of nuclei, the final nanocrystal size at full conversion, and the elemental composition. The utility of controlled reactivity for adjusting alloy microstructure is discussed.

Bis-(triethylphosphine)platinum(II) complexes with thiones as anti cancer agents

Platinum(II) complexes having mixed ligands as anticancer agents. The central platinum atom is coordinated by two phosphine ligands and two heterocyclic thione ligands. Each heterocyclic thione ligand has a five-, six- or seven-membered heterocyclic ring with two nitrogen atoms at positions 1 and 3 of the ring and a thiocarbonyl group at position 2. Pharmaceutical compositions incorporated the platinum(II) complexes, methods of synthesizing the complexes and methods of treating cancers with the complexes or pharmaceutical compositions thereof are also described.